GLP-1s and Erectile Function: What ENDO 2026 Confirmed

ENDO 2026 presented data showing tirzepatide delivered improved erectile function compared to testosterone replacement therapy in men with functional hypogonadism — the obesity-driven form of low testosterone.

The Data

This finding connects three dots that matter for men: excess body fat suppresses testosterone through aromatase conversion, low testosterone impairs erectile function, and GLP-1 medications restore natural testosterone by addressing the underlying fat-driven suppression. The erectile function improvement isn't a primary pharmacological effect of GLP-1 drugs — it's a downstream consequence of restoring the hormonal environment that supports normal sexual function. For men experiencing ED alongside obesity and low testosterone, GLP-1 treatment may address all three simultaneously without the fertility risks of TRT or the cardiovascular concerns of PDE5 inhibitors at higher doses.

What This Means for You

This doesn't mean GLP-1s replace ED medications for men with normal weight and normal testosterone. The benefit is specific to the obesity-hypogonadism-ED cascade..

The Practical Application

.

Providers Worth Considering